Asarina Pharma
Solna
About Asarina Pharma
Asarina Pharma AB is a Swedish biotech company focusing on the development of Sepranolone (UC1010) for the treatment of premenstrual dysphoric disorder and other menstrually related conditions. The company's primary goal is to offer a novel therapy that is specifically designed for PMDD. Asarina has a second generation oral compound in preclinical development for PMDD
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $24.8M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2018)
- Ticker: nasdaq:ASAP
- Website: asarinapharma.com
- Phone: +46 8 524 844 84
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/asarina-pharma-2202753 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.